Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Ho-Jun | - |
dc.contributor.author | Park, Sang-Don | - |
dc.contributor.author | Park, Hyun Woo | - |
dc.contributor.author | Suh, Jon | - |
dc.contributor.author | Oh, Pyung Chun | - |
dc.contributor.author | Moon, Jeonggeun | - |
dc.contributor.author | Lee, Kyounghoon | - |
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Kwon, Sung Woo | - |
dc.contributor.author | Kim, Tae-Hoon | - |
dc.date.accessioned | 2021-08-11T14:44:26Z | - |
dc.date.available | 2021-08-11T14:44:26Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 1170-229X | - |
dc.identifier.issn | 1179-1969 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7548 | - |
dc.description.abstract | Objectives Compared with dual antiplatelet therapy including aspirin and clopidogrel, triple antiplatelet therapy including cilostazol has a mortality benefit in patients with ST-segment elevation myocardial infarction. However, whether the mortality benefit persists in elderly patients is not clear. Methods From 2007 to 2014, 1278 patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention were retrospectively analyzed. The patients were divided into four groups by age (<75 or >= 75 years; young and elderly, respectively) and antiplatelet strategy ( triple or dual antiplatelet therapy). We compared the mortality rates between the triple and dual antiplatelet therapy groups. Results There were 1052 (male, 85%; mean age, 56.3 +/- 10.4 years) patients in the young group and 241 (male, 52.7%; mean age, 80.3 +/- 4.5 years) patients in the elderly group. In the young and elderly groups, 220 (20.9%) and 28 (12.3%) patients were treated with triple antiplatelet therapy. During a 1-year follow-up period, 80 patients died (4.2% in the young group vs. 15.5% in the elderly group). Kaplan-Meier survival analysis revealed that triple antiplatelet therapy was associated with a lower mortality rate in the young group (log-rank, p = 0.005). Although there were more angiographic high-risk patients in the elderly group, similar mortality rates were reported (log-rank, p = 0.803) without increased bleeding rates (1 vs. 3.6% in the elderly group, p = 0.217). Conclusions Triple antiplatelet therapy might be a better antiplatelet regimen than dual antiplatelet therapy for patients with ST-segment elevation myocardial infarction. Although this benefit was strong in patients aged <75 years, no definite increase in major bleeding was seen for elderly patients (aged >= 75 years). | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Adis International Ltd. | - |
dc.title | Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry | - |
dc.type | Article | - |
dc.publisher.location | 뉴질랜드 | - |
dc.identifier.doi | 10.1007/s40266-017-0463-9 | - |
dc.identifier.wosid | 000401319400006 | - |
dc.identifier.bibliographicCitation | Drugs and Aging, v.34, no.6, pp 467 - 477 | - |
dc.citation.title | Drugs and Aging | - |
dc.citation.volume | 34 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 467 | - |
dc.citation.endPage | 477 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Geriatrics & Gerontology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Geriatrics & Gerontology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ELUTING STENT IMPLANTATION | - |
dc.subject.keywordPlus | RANDOMIZED-TRIALS | - |
dc.subject.keywordPlus | ADDING CILOSTAZOL | - |
dc.subject.keywordPlus | TASK-FORCE | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordAuthor | Triple antiplatelet therapy might be a better antiplatelet regimen than dual antiplatelet therapy for patients with ST-segment elevation myocardial infarction. Although this benefit was strong in patients aged <75 years | - |
dc.subject.keywordAuthor | no definite increase in major bleeding was seen for elderly patients (aged ≥75 years). | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.